High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vγ9Vδ2 T-cell chemotaxis and cytotoxicity in vivo

Cancer Research

Volumn 71, Issue 13, 2011, Pages 4562-4572

  Benzaïd, Ismahène ^a,b   Mönkkönen, Hannu ^a,b   Stresing, Verena ^a,b   Bonnelye, Edith ^a,b   Green, Jonathan ^d   Mönkkönen, Jukka ^d   Touraine, Jean Louis ^c   Clézardin, Philippe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE LYON   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BISPHOSPHONIC ACID DERIVATIVE; ESTER DERIVATIVE; GERANYLTRANSFERASE; INTERLEUKIN 2; ISOPENTENYL DIPHOSPHATE; MEVALONIC ACID; PHOSPHOANTIGEN; PLACEBO; TRIPHOSPHORIC ACID I ADENOSINE 5' YL ESTER 3 (3 METHYLBUT 3 ENYL)ESTER; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ACTIVITY; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CHEMOTAXIS; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR XENOGRAFT; VGAMMA9VDELTA2 T LYMPHOCYTE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; FEMALE; HEMITERPENES; HUMANS; IMIDAZOLES; MICE; MICE, INBRED NOD; MICE, SCID; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHORYLATION; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 79959916377     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3862     Document Type: Article

References (33)

1. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26.
2. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone In press 2011.
3. Clézardin P. Bishosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 2011;48:71-9.
4. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91.
5. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving letrozole: 36 months results of the ZO-FAST study. Ann Oncol 2010;21:2188-94.
6. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099-105.
7. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-92.
8. Miyagawa F, Tanaka Y, Yamashita S, Minato N. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol 2001;166:5508-14.
9. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003;102:2310-1.
10. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8.
11. Tanaka Y. Human g T cells and tumor immunotherapy. J Clin Exp Hematopathol 2006;46:11-23.
12. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009;144:245-50.
13. Monkkonen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsäläinen J, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006;147:437-45.
14. Vantourout P, Mookerjee-Basu J, Rolland C, Pont F, Martin H, Davrinche C, et al. Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J Immunol 2009;183:3848-57.
15. Kabelitz D, Wesch D, Pitters E, Zöller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol 2004;173:6767-76.
16. Marten A, Lilienfeld-Toal M, Buchler MW, Schmidt J. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J. Immunother 2007;30:370-7.
17. Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother 2007;56:1285-97.
18. Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J, et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005;116:94-9.
19. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, et al. Efficient killing of human colon cancer stem cells by γ T lymphocytes. J Immunol 2009;182:7287-96.
20. Yuasa T, Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N, et al. Intravesical administration of gamma delta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Imunol Immunother 2009;58:493-502.
21. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, et al. Vgamma9Vdelta2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 2010;184:3260-8.
22. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-6.
23. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67:7450-7.
24. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010;161:290-7.
25. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009;58:31-8.
26. Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2T cells: discreminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev 2007;215:59-76.
27. Mönkkönen H, Kuokkanen J, Holen I, Evans A, Lefley DV, Jauhiainen M, et al. 2008. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer. Drugs 19:391-399.
28. Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001;16:2027-34.
29. Sanders JM, Ghosh S, Chan JM, Meints G, Wang H, Raker AM, et al. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem 2004;47:375-84.
30. Bonneville M, O'Brien RL, Born WK. g T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010;10:467-78.
31. Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006;69:1624-32.
32. Borgquist S, Djerbi S, Pontén F, Anagnostaki L, Goldman M, Gaber A, et al. HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. Int J Cancer 2008;123:1146-53.
33. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010;126:239-46.